BofA upgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Underperform with a price target of $445, up from $266.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- MDGL Upcoming Earnings Report: What to Expect?
- Sagimet Biosciences initiated with a Buy at Clear Street
- Madrigal Pharmaceuticals price target raised to $540 from $400 at Piper Sandler
- Madrigal Pharmaceuticals: Strong Growth Potential Driven by Rezdiffra’s Market Leadership and Strategic Opportunities
- Madrigal Pharmaceuticals initiated with a Buy at Truist